⌕
Inhibrx Biosciences · INBX · Nasdaq
Tenet 45 · Mixed
Compare
$74.18−4.48%At closeTenet 45 · Mixed
$74.18−3.48 (−4.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Inhibrx Biosciences (INBX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 17, 2026 · 16:53 ETCOMPANY'S OWN WORDS
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma

- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, I…

● PRNewsWireNov 13, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Inhibrx Reports Third Quarter 2026 Financial Results

SAN DIEGO, Nov. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in…

● Defense WorldOct 27, 2026 · 04:13 ET
Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.47 and traded as low as $86.92. Inh…

● PRNewsWireOct 13, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeu…

● Defense WorldOct 5, 2026 · 08:14 ET
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast

Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies bas…

● MarketBeatOct 2, 2026 · 08:00 ET
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical outperformance that the broade…

● Defense WorldSep 30, 2026 · 06:44 ET
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) rose 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $101.44 and last traded at $103.2880. Ap…

● Defense WorldSep 30, 2026 · 06:00 ET
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price was up 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $101.44 and last traded …

● Defense WorldSep 25, 2026 · 04:23 ET
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem bought 5,000 shares of Inhibrx Biosciences stock in a transaction on Wednesday, September 23rd. The stock was purchased at an average price o…

● Defense WorldSep 20, 2026 · 05:10 ET
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem purchased 5,000 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was purchased at an average cost of…

● The Motley FoolSep 15, 2026 · 20:09 ET
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held before the filing.…

● Seeking AlphaSep 14, 2026 · 09:46 ET
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106

Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma was accepted by the F…

● Seeking AlphaSep 9, 2026 · 08:10 ET
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom

Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarc…

● BenzingaSep 8, 2026 · 11:29 ET
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.…

● ReutersSep 8, 2026 · 08:19 ET
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a ​mid-stage study in patients with a type of ‌head and neck cancer.…

● PRNewsWireSep 8, 2026 · 07:30 ET
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and   72.4% of patients remain progression free at 6 months, compared with 26.5% and   42.8%   f…

● PRNewsWireSep 4, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just INBX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.